Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 16 of 5804
-
One-Time gene injection aims to halt rare blindness
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the safety and early effectiveness of ZVS101e in patients with Bietti crystalline dystrophy who meet the eligibility criteria for treatment under the translational application program in the Hainan Boao Lecheng International Medical …
Phase: NA • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Magic mushroom compound could lift Veterans' depression
Symptom relief Not yet recruitingThe purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Promising antibody trial aims to halt rare bone disease in kids
Disease control Not yet recruitingThis study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at sev…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New weight-loss drug aims for lasting results in large phase 3 trial
Disease control Not yet recruitingThe primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug shows promise for sustained weight loss in type 2 diabetes
Disease control Not yet recruitingThe primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingBackground: Myeloid cells are a type of immune cell found in most tumors. Interleukin 12 (IL-12) is a protein that helps the immune system kill tumor cells. Researchers want to know if myeloid cells that have been genetically engineered to produce IL-12 (IL-12 GEMys) can activat…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could atomoxetine or metformin be the next Alzheimer's treatment?
Disease control Recruiting nowA multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzh…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
Disease control Not yet recruitingThis Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a …
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Gene therapy breakthrough? new trial targets rare brain disorder FOXG1
Disease control ENROLLING_BY_INVITATIONThe goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.
Phase: PHASE1, PHASE2 • Sponsor: FOXG1 Research Foundation • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
Disease control Not yet recruitingThis is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
In-Womb procedure aims to save babies from deadly brain malformation
Disease control Recruiting nowThis is a prospective, single-arm non-randomized interventional study of fetuses to assess the efficacy and safety of fetal embolization of VOGM. Subjects will receive a one-time study intervention of fetal embolization, at or after 34 weeks of gestation. After delivery, neurolog…
Phase: NA • Sponsor: Darren Orbach • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental drug aims to stop liver failure in MASH cirrhosis
Disease control Not yet recruitingThis study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental drug aims to reverse liver scarring in MASH cirrhosis
Disease control Not yet recruitingThis is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusio…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a 'Sandwich' of drugs beat Full-Course immunotherapy for a tough head and neck cancer?
Disease control Recruiting nowImmunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade. Existing evidence supports synergistic anti-tumor activity between the a…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Triple immunotherapy cocktail aims to boost surgery success in liver cancer
Disease control Not yet recruitingThe purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Breath of life: new test could sniff out gut cancers before they spread
Diagnosis Not yet recruitingThe investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel. These cancers often cause non-specific symptoms that are similar to beni…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Can a Two-Drug cocktail keep bladder cancer from coming back?
Disease control Recruiting nowPurpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection. Study details: Duration: \~78 months (6.5 years) from FSI to last subject visit Treatment length: up t…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test
Disease control Not yet recruitingLiver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives. Apixaban is already commonly used to prevent or treat blood clots and is know…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill takes on tough lung cancer mutation
Disease control Not yet recruitingThe purpose of this study is to compare the effectiveness, safety and tolerability of GFH375 versus docetaxel in participants with KRAS G12D-mutant non-small cell lung cancer (NSCLC). GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer
Disease control Recruiting nowAlthough immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients with esophageal cancer remains unsatisfactory, with a…
Sponsor: Fudan University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC